They dont cherry pick results as much as they cherry pick the patients that are candidates for the protocols. By selecting patients with better prognostic features, health etc they in effect have a patient population that will survive longer than expected. At the conclsion of phase 2 they more often cherry pick endpoints that they then use in phase 3.